CHESTER, NY / May 15, 2017 / Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) (“RMS” or the “Company”) announced today it will be launching a new social media marketing campaign at the National Home Infusion Association (NHIA) in Orlando Florida on May 22, 2017. NHIA is one of the largest U.S. tradeshows … Continued
CHESTER, NY / April 10, 2017 / Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) (“RMS” or the “Company”) is pleased to announce that the umbrella organization of the public health insurance in Germany approved the FREEDOM60® Infusion System for reimbursement. The FREEDOM60® System was registered January, 31st 2017 and listed in the … Continued
CHESTER, NY / April 3, 2017 / Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) (“RMS” or the “Company”) announced today it has strengthened its Global Sales and Marketing team by hiring Steven Kamphausen as Global VP, Sales and Marketing. Steve comes to us by way of Toyota Tsusho America from a senior … Continued
CHESTER, NY / March 27, 2017 / Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) (“RMS” or the “Company”) announced today the successful launch of a new product.
CHESTER, NY / January 20, 2017 / Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) (“RMS” or the “Company”) announced today that Mr. Eric Bauer has joined the executive team as Chief Operating Officer, effective January 17, 2017. Mr. Bauer brings to RMS over 25 years of experience driving operational excellence in growing … Continued
The Company announced that its net revenues for the third quarter ended November 30 of fiscal 2017 were $3,193,113 compared with $3,144,954 for the third quarter of fiscal 2016. Net loss for the quarter was $104,275 compared with net income of $167,552 for the same period last year. For the nine months ended November 30, … Continued
In this edition of RMS Connections, we discuss our recent tradeshows along with office holiday highlights.
Effective May 13, 2016, Joseph Manko, Jr. was appointed as an additional member of the Board of Directors of Repro Med Systems, Inc. Mr. Manko is the Senior Principal in Horton Capital Management LLC, the investment manager for the Horton Capital Partners Fund, LP (“Horton Fund”). The Horton Fund is a significant shareholder in the … Continued
On April 26, 2016, the Board of Directors of Repro Med Systems, Inc. (the “Company”) appointed Mr. Cyril Narishkin as President of the Company to replace Mr. Andrew Sealfon. Mr. Sealfon remains as the Company’s Chief Executive Officer and head of research and development.
Q When did RMS receive the warning letter? A RMS received the FDA Warning Letter (WL) on Monday, February 29, 2016. Q What does it mean to receive a WL? A As explained by the FDA in its Regulatory Procedure Manual Chapter 4, an FDA warning letter “…is informal and advisory”; “does not commit FDA … Continued
